Investors from Pendal, First Sentier and Allen Grey are betting on some out-of-favour market darlings of the ASX.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The results of the Swiss Health Survey 2022 reveal clear differences between men and women: 55% of women and 44% of men live ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

Despite its popularity, Ozempic often leads to temporary weight loss, carries serious side effects, and most users regain ...